TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06910657: IDOV-Immune for Advanced Solid Tumors

Sponsor: ViroMissile, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 78 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$8,670,816

Rescue Site Savings

+$5,717,712

Unlock Full NCT06910657 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06910657 Rescue Dossier →